16 April 2019
Amyloid fibrils are misfolded proteins which have assembled to form insoluble aggregates in the form of fibers that are resistant to degradation. Amyloid formation is often associated with a disease that is specific to the proteins or localisation of the aggregate. Well known examples of amyloid diseases include Alzheimer’s disease, Diabetes type 2 […]
16 April 2019
9th April 2019
Changes in the glycosylation pattern of cell surface and secreted glycoproteins are common in malignant transformations and cancer progression, (1). Prostate-specific antigen (PSA), is a glycoprotein enzyme secreted by the prostate gland that is often used for diagnosing and predicting progression of prostate cancer in men. Recent advances in the field of glycobiology […]
2nd April 2019
Post Translational Modifications (PTM) are biochemical variations of cetain amino acids made to a protein after biosynthesis. These modifications diversify the proteome and play a fundamental role in regulation and targeting of proteins, their interactions with other molecules, as well as their structure, activity and function. Common types of post-translational modifications include phosphorylation, […]
3rd October 2018
Proprietary process with validated improvement in delivery and performance
OptimersTM in 12 weeks
Aptamer Group is pleased to announce availability of OptimersTM – the new standard for our custom development services.
Aptamer Group is dedicated to continually improve its service offerings to identify the best reagent(s) from within our vast aptamer libraries in the […]
29th August 2018
At Aptamer Group, every custom aptamer project begins with a feasibility study. The target and assay matrix are tested for compatibility and stability with the aptamer library, under a variety of conditions. At this early stage it is important to understand the optimal strategy for the selection, address any potential issues and […]
9th August 2018
Aptamers continue to demonstrate advantages in platforms and applications which require specific detection of small molecule targets.
There has been a growth in the use of point of care devices across a range of applications and assay types due to a need for rapid and reliable analysis (Vashist 2017). Aptamers are perfectly suited for […]
Arron Tolley, CEO – I’m delighted to announce that Aptamer Group Ltd, has recently closed its Series A investment round; attracting international interest and securing $2.2m of funding from overseas investors, to support its pioneering aptamer development pipeline.
Aptamer technology is rapidly evolving and will continue to have a significant impact on the life sciences market […]
22nd June 2018
Changes in hormone levels can be key indicators to a variety of issues, examples include testosterone levels in general health and well being(1) and diagnosing Cushing’s disease involving the steroid cortisol (2). While these small molecules and others are well documented and their role in health and disease is becoming better understood, researchers […]
Aptamers excel as binding reagents in ELISA replacement assays for antibiotics in complex media such as plasma, milk and others
18th May 2018.
Traditionally small molecules, such as antibiotics, have been difficult targets for ELISA development. Aptamer Group has selected aptamers that bind to small molecules, previously inaccessible to other binding technologies. Utilising our state-of-the-art automation and parallel processing techniques, we can select high affinity and highly specific aptamers against small molecule targets, in solution. These […]
4th May 2018
Development of biosensors for the detection of small molecules is notoriously difficult due to the lack of suitable antibodies and the relatively small signals, which result upon small molecule binding to them. At Aptamer Group we select aptamers that bind to small molecules with high specificity and undergo a substantial conformational change that gives […]